Target intelligence / Profile preview

Envelope glycoprotein gp120 (HIV-1 IIIB) (gp120)

Target
gp120
Molecular classification
Viral envelope glycoprotein, Receptor-binding protein, Other
01

Overview

Envelope glycoprotein gp120 is a heavily glycosylated, surface-exposed protein on the HIV-1 viral envelope that forms a trimeric complex with the transmembrane glycoprotein gp41, collectively termed Env. gp120 is essential for viral entry, mediating binding to the CD4 receptor on host T-cells, followed by interaction with a chemokine coreceptor (usually CCR5 or CXCR4), triggering conformational changes that enable the fusion of viral and cellular membranes. The protein is the primary target for broadly neutralizing antibodies and is central to immune evasion due to its glycan shield and sequence variability. gp120 is derived from proteolytic cleavage of gp160 and remains associated with gp41 via non-covalent bonds. The subtype "HIV-1 IIIB" refers to a well-characterized laboratory strain frequently used in structural and drug development studies.

Other names
HIV-1 gp120HIV envelope glycoproteinSU (surface unit)HIV-1 Env (with gp41)
02

Mechanism of action

Inhibition of CD4-gp120 binding; Prevention of conformational changes essential for membrane fusion; Neutralization of virus by steric hindrance or glycan locking

03

Biological functions

Virus entry into host cellAttachment to cell surface receptor (CD4)Interaction with chemokine coreceptors (CCR5/CXCR4)Immune evasion (glycan shield)
04

Disease associations

Infection (specifically HIV/AIDS)
05

Safety considerations

High mutational variability leading to resistanceGlycan shield limiting antibody accessibilityOff-target immune effects/autoimmunity risk with some therapies
06

Interacting drugs

Ibalizumab (monoclonal antibody)

2 more in the full profile.

07

Biomarkers

gp120-specific antibodies (monitored in vaccine development and serological tests)Envelope diversity and tropism markers for therapeutic selection

Beyond the preview

Go deeper on Envelope glycoprotein gp120 (HIV-1 IIIB) (gp120).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Envelope glycoprotein gp120 (HIV-1 IIIB) (gp120).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call